Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:02:35.963Z.
Consensus retrieved: 2026-10-06T11:32:54.099Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:02:35.963Z.
Quote observation: 2026-10-06T15:00:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b51c0f44cebcda92df36ba84a4acb5d87636d796a0a5ea1dda07c69c0f8d54a9
Forward PE Ratio (N/A) = Dated Quote Price ($21.19) / Consensus Forward EPS ($-2.27)
FORWARD PE RATIO
N/A
Fulgent Genetics, Inc.
Market Cap
$601.74M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | $601.74M | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $605.01M | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 2.97 |
| AngioDynamics, Inc. (ANGO)vs › | $610.07M | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $582.15M | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $568.99M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $637.34M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $563.87M | N/A |
| CorMedix Inc. (CRMD)vs › | $563.68M | 14.52 |
| OmniAb, Inc. (OABI)vs › | $640.05M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $21.19, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.27 | $-2.27 – $-2.27 | 1 | n/m |
| 2027-12-31 | $-1.38 | $-1.38 – $-1.38 | 1 | n/m |
| 2028-12-31 | $-1.18 | $-1.18 – $-1.18 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
